News | June 14, 2010

Radio Tracer Grows at Rapid Rate

June 14, 2010 – A radio tracer is quickly gaining popularity among cardiologists in the United States.

Bracco Diagnostics Inc. recently announced that its CardioGen-82 (rubidium Rb 82 generator) is achieving unprecedented growth in the United States. Over the past five years, CardioGen-82 has experienced double-digit year-over-year growth, with a marked increase recorded in the past nine months. [1] Cardiologists, radiologists, and nuclear medicine physicians will perform an estimated 145,000 positron emission tomography (PET) myocardial perfusion imaging (MPI) procedures in 2010 using CardioGen-82. [2]

Several key factors have contributed to this growth, including increasing momentum for the modality of cardiac PET, publication of key clinical data, and improvements in PET hardware/software technology and accessibility.

CardioGen-82 is the only FDA-approved generator-based PET MPI tracer reimbursed for the evaluation of coronary artery disease (CAD). [3]

As the significant shortage of SPECT (single photon emission computed tomography) MPI tracers made using Mo-99 continues, many nuclear cardiology labs have adopted cardiac PET with CardioGen-82 as a standard of patient care. With the closing of both National Research Universal’s Chalk River reactor in Canada – the source of more than half the world’s supply of Mo-99 – and the Petten reactor in the Netherlands, and no short-term fix in sight, health care providers face significant pressure to find alternate ways to meet the needs of their CAD patients beyond the standard practices they have typically and previously employed.

Since PET MPI procedures can be performed in as little as 30 minutes or less, there are great efficiencies offered by this technique. [4, 5] “The reduced scan time compared with SPECT helps to improve patient satisfaction,” says referring cardiologist Kyle Richards, M.D. of Pioneer Valley Cardiology in Springfield, Mass.

Moreover, PET MPI offers greater interpretive certainty for imagers, according to a publication in the Journal of Nuclear Cardiology by Tim Bateman, M.D. of Cardiovascular Consultants in Kansas City, Mo., and his colleagues: “A significantly lower percent (81 percent) of SPECT scans were able to be interpreted as definitely normal or abnormal compared with 96 percent of PET images (p=.0008).” [5]

For more information: www.cardiogen.com.

References:

[1] Bracco Sales Data on file

[2] Bio-Tech Systems, Inc. PET Market Report July 2009

[3] Medicare National Coverage Determination 220.6.1

[4] Dorbala S., Hachamovitch R., Curillova Z., et al. “Incremental Prognostic Value of Gated Rb-82 Positron Emission Tomography Myocardial Perfusion Imaging Over Clinical Variables and Rest LVEF.” Journal of the American College of Cardiology. 2009;2;846-854.

[5] Bateman T.M., Heller G.V., McGhie A.l., et al. “Diagnostic accuracy of rest/stress ECG-gated Rb-82 myocardial perfusion PET: comparison with ECG-gated Tc-99m sestamibi SPECT.” Journal of Nuclear Cardiology. 2006;13:24-33.

Related Content

PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment

Longitudinal PET imaging with 18F-AV45. PET imaging shows the average 18F-AV45 uptake per animal group at 8 and 13 months of age. A significant interaction of genotype treatment was observed in the cortex (p = 0.0248), hippocampus (p = 0.0071) and thalamus (p = 0.0084), indicating reduced [18F]-AV45 uptake in BACE1 inhibited transgenic mice. Credit: MICA, University of Antwerp, Belgium.

News | Radiopharmaceuticals and Tracers | December 28, 2017
In the December featured basic science article in The Journal of Nuclear Medicine, Belgian researchers report on the...
Vital Unveils Newest Vitrea Advanced Visualization Release at RSNA 2017
Technology | Advanced Visualization | December 04, 2017
Vital Images unveiled the newest version of Vitrea Advanced Visualization software, the cornerstone of its imaging...
Michael J. Fox Foundation and Tau Consortium Developing PET Tracers for Neurodegenerative Disease
News | Radiopharmaceuticals and Tracers | October 27, 2017
The Michael J. Fox Foundation for Parkinson's Research (MJFF) and the Tau Consortium announced a funding partnership to...
Netherlands Cancer Institute Exploring Molecular Imaging Technology for Prostate Cancer Surgery
News | Molecular Imaging | October 26, 2017
The Netherlands Cancer Institute (NKI) announced it has received funding from the Dutch Cancer Society (KWF...
SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Biodex Unveils Atomlab 500 Dose Calibrator and Wipe Test Counter
Technology | Nuclear Imaging | October 19, 2017
Biodex Medical Systems announced the full release of the Atomlab Dose Calibrator and Wipe Test Counter to the market...
ASNC and ASE Team Up to Expand ImageGuide Registry
News | Cardiovascular Ultrasound | October 12, 2017
The American Society of Nuclear Cardiology (ASNC) and the American Society of Echocardiography (ASE) jointly announced...
MR Solutions Showcases Multimodality MRI Solutions on Two Continents
News | Magnetic Resonance Imaging (MRI) | October 11, 2017
October 11, 2017 — MR Solutions took their cryogen-free preclinical multimodality...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
News | Business | September 19, 2017
September 19, 2017 — Invicro LLC, a provider of imaging services and software for research and drug development, anno
Overlay Init